Valbiotis

Regulatory Filings • Jan 12, 2026

{0}------------------------------------------------

Press release

Valbiotis announces a major new scientific publication on TOTUM-448, an active substance designed to treat metabolic liver disease (MASLD)

• The article on TOTUM•448 was published in Scientific Reports, a recognized international peerreviewed journal
• This is the third scientific publication focusing on TOTUM•448 and the first publication presenting results from a study conducted in humans
• The results confirm the bioavailability of TOTUM•448 and describe its mode of action on human liver cells

La Rochelle, 12 January 2026 (5:40 p.m. CEST) – Valbiotis (FR0013254851 – ALVAL, eligible for PEA / SME classification), is a French laboratory specialized in the design and distribution of scientifically tested dietary supplements to support health at every stage of life. Valbiotis announces a new scientific publication for TOTUM•448* , an active substance for metabolic liver diseases, in the international journal Scientific Reports.

This new publication marks Valbiotis' 15th scientific publication, confirming its well- structured and continuous research program.

Scientific advances and research partnership

This publication demonstrates, for the first time in humans, the bioavailability of the TOTUM•448 substance as well as several characteristics of its mode of action on human liver cells, including the reduction of intracellular lipids and, in particular, inflammation and stress in the reticulum. This third publication is further proof of the scientific potential of TOTUM•448.

The study was conducted in partnership with Clinic'n'Cell, and with the collaboration of MetaboHUB, the University of Bordeaux, INRAE, CIC INSERM in Clermont-Ferrand, Clermont Auvergne University and Clermont-Ferrand University Hospital.

Pascal Sirvent, Scientific Director, PhD, HDR, member of the Executive Board: 'We are delighted to see our work recognized by an international scientific journal. This publication showcases both the strength of our research and development as well as the scientific progress we are making in collaboration with academic and university partners to better understand the active substance TOTUM•448 and its impact on liver health.'

{1}------------------------------------------------

Additional publications are expected in 2026 on the in-depth mode of action of TOTUM•448 and its effects on the gut microbiota. The results of the Cardio-Liver clinical study, currently being conducted in Canada, are also expected soon, as recruitment has recently been finalized.

A product that will join the ValbiotisPRO® range with a view to its roll-out in France, Asia and the Middle East

Building on its scientific successes, TOTUM•448 will strengthen the commercial appeal of the ValbiotisPRO® range, which benefits from a high level of clinical evidence and currently includes three dietary supplements already on the market (ValbiotisPRO® Cholesterol, ValbiotisPRO® Metabolic Health, ValbiotisPRO® Cardio-Circulation). With considerable market potential in the prevention of metabolic liver diseases, TOTUM•448 will benefit from multi-channel marketing when it is launched in France, supported by a rapidly growing presence in pharmacies and the valbiotis.com e-commerce site. Internationally, the product will be fully integrated into the commercial deployment strategy in Asia, as part of the joint venture with Aika announced on 17 November, as well as in the Middle East, following the distribution agreement signed on 8 January with Meta Nutrition.

*https://www.nature.com/articles/s41598-025-32556-z

About Valbiotis

Valbiotis is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com

Contacts

Corporate Communication / Valbiotis Caroline LAMBERTI + 33 6 77 82 56 88 caroline.lamberti@valbiotis.com

Financial Communication / Seitosei.Actifin Marianne PY +33 6 85 52 76 93

marianne.py@seitosei-actifin.com

Name: Valbiotis ISIN Code: FR0013254851 Ticker Symbol: ALVAL EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.